Ekso Bionics Holdings, Inc.

Greetings. Welcome to the Exobionics third quarter 2021 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Matt Steinberg. You may begin.

Thank you, Operator, and thank you all for participating in today's call. Joining me from Exobionics are Jack Purek, President and Chief Executive Officer, Jack Glenn, Chief Financial Officer, and Bill Shaw, Chief Commercial Officer. Earlier today, Exobionics released financial results for the quarter ended September 30th, 2021. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements including our future financial or operational expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, You should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. EXCO disclaims any intention or obligation, except as required by law, to update or revise any financial or operational projections, our regulatory outlook, or other forward-looking statements whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the broadcast today, November 2nd, 2021. I will now turn the call over to ExoBionics CEO, Jack Purack.

Thanks, Matt, and thanks, everybody, for joining us today. The third quarter reflected continued execution across our company as we reported improved revenues on both an annual and sequential basis. In the rehabilitation segment, we made significant progress with top inpatient rehabilitation network operators, and in the industrial segment, we were able to win material orders with both existing and new companies in the automotive and aerospace segments. Our flexible commercial offerings, which include capital sales and subscriptions, are giving our customers acquisition options And we are encouraged by an increasing level of customer interest and engagement as evidenced by a growing sales pipeline in all segments. For the third quarter, we generated solid revenue of $3 million, up 38% on a sequential basis. On the ExoHealth side of the business, we recorded 16 ExoNR bookings. While we continue to drive adoption of our subscription model, which provides purchasing flexibility for our customers, Nearly all of our bookings in the quarter were through capital purchases. As a result of the capital purchases this quarter, we generated two subscription bookings this quarter. On the industrial side, we are driving continued high level of customer interest via onsite evaluations. And our commercial team has produced several initial orders with leading companies, particularly in the automotive vertical with some of the newer participants in that industry. We remain focused on building greater awareness of our innovative EVO and XO-0G products. Now I will turn the call over to Bill for an update on our medical segment and global commercial strategy.